Insights on neoplastic stem cells from gel-based proteomics of childhood germ cell tumors

Pediatric Blood and Cancer

Volumn 58, Issue 5, 2012, Pages 722-728

  Haskins, William E ^a,b   Eedala, Sruthi ^a   Avinash Jadhav, Y L ^a   Labhan, Manbir S ^a   Pericherla, Vidya C ^a   Perlman, Elizabeth J ^c  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Childhood germ cell tumor; Glucocorticoid receptor signaling; Neoplastic stem cells; Proteomics

Indexed keywords

AMINO ACID SEQUENCE; ARTICLE; CELL DIFFERENTIATION; CELL RENEWAL; CHILDHOOD CANCER; DYSGERMINOMA; GEL; GERM CELL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DATABASE; PROTEOMICS; STEM CELL; TUMOR MICROENVIRONMENT; UPREGULATION; YOLK SAC TUMOR;

ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOPLASTIC STEM CELLS; NUCLEAR FACTOR 45 PROTEIN; PROTEOMICS; RECEPTORS, GLUCOCORTICOID; RETINOBLASTOMA-BINDING PROTEIN 4; TACROLIMUS BINDING PROTEINS;

EID: 84857833232     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23282     Document Type: Article

References (50)

1. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
2. Dick JE. Stem cell concepts renew cancer research. Blood 2008; 112: 4793-4807.
3. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007; 448: 313-317.
4. Mullen EM, Gu P, Cooney AJ. Nuclear receptors in regulation of mouse ES cell pluripotency and differentiation. PPAR Res 2007; 2007: 61563.
5. Bussey KJ, Lawce HJ, Olson SB, et al. Chromosome abnormalities of eighty-one pediatric germ cell tumors: Sex-, age-, site-, and histopathology-related differences-A Children's Cancer Group study. Genes Chromosomes Cancer 1999; 25: 134-1146.
6. Juric D, Sale S, Hromas RA, et al. Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures. Proc Natl Acad Sci USA 2005; 102: 17763-17768.
7. Zimmermann U, Junker H, Kramer F, et al. Comparative proteomic analysis of neoplastic and non-neoplastic germ cell tissue. Biol Chem 2006; 387: 437-440.
8. Sperger JM, Chen X, Draper JS, et al. Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. Proc Natl Acad Sci USA 2003; 100: 13350-13355.
9. Looijenga LH, Stoop H, de Leeuw HP, et al. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res 2003; 63: 2244-2250.
10. Ezeh UI, Turek PJ, Reijo RA, et al. Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 2005; 104: 2255-2265.
11. Hart AH, Hartley L, Parker K, et al. The pluripotency homeobox gene NANOG is expressed in human germ cell tumors. Cancer 2005; 104: 2092-2098.
12. Honecker F, Stoop H, Mayer F, et al. Germ cell lineage differentiation in non-seminomatous germ cell tumours. J Pathol 2006; 208: 395-400.
13. Hoei-Hansen CE, Sehested A, Juhler M, et al. New evidence for the origin of intracranial germ cell tumours from primordial germ cells: Expression of pluripotency and cell differentiation markers. J Pathol 2006; 209: 25-33.
14. Rajpert-De Meyts E, Hanstein R, Jorgensen N, et al. Developmental expression of POU5F1 (OCT-3/4) in normal and dysgenetic human gonads. Hum Reprod 2004; 19: 1338-1344.
15. Palumbo C, van Roozendaal K, Gillis AJ, et al. Expression of the PDGF alpha-receptor 1.5kb transcript, OCT-4, and c-KIT in human normal and malignant tissues. Implications for the early diagnosis of testicular germ cell tumours and for our understanding of regulatory mechanisms. J Pathol 2002; 196: 467-477.
16. Almstrup K, Hoei-Hansen CE, Wirkner U, et al. Embryonic stem cell-like features of testicular carcinoma in situ revealed by genome-wide gene expression profiling. Cancer Res 2004; 64: 4736-4743.
17. Almstrup K, Hoei-Hansen CE, Nielsen JE, et al. Genome-wide gene expression profiling of testicular carcinoma in situ progression into overt tumours. Br J Cancer 2005; 92: 1934-1941.
18. de Jong J, Looijenga LH. Stem cell marker OCT3/4 in tumor biology and germ cell tumor diagnostics: History and future. Crit Rev Oncog 2006; 12: 171-203.
19. Stoop H, Honecker F, van de Geijn GJ, et al. Stem cell factor as a novel diagnostic marker for early malignant germ cells. J Pathol 2008; 216: 43-54.
20. Cheng L, Sung MT, Cossu-Rocca P, et al. OCT4: Biological functions and clinical applications as a marker of germ cell neoplasia. J Pathol 2007; 211: 1-9.
21. Kao PN, Chen L, Brock G, et al. Cloning and expression of cyclosporin A- and FK506-sensitive nuclear factor of activated T-cells: NF45 and NF90. J Biol Chem 1994; 269: 20691-20699.
22. Doerks T, Copley RR, Schultz J, et al. Systematic identification of novel protein domain families associated with nuclear functions. Genome Res 2002; 12: 47-56.
23. Corthesy B, Kao PN. Purification by DNA affinity chromatography of two polypeptides that contact the NF-AT DNA binding site in the interleukin 2 promoter. J Biol Chem 1994; 269: 20682-20690.
24. Cox MB, Riggs DL, Hessling M, et al. FK506-binding protein 52 phosphorylation: A potential mechanism for regulating steroid hormone receptor activity. Mol Endocrinol 2007; 21: 2956-2967.
25. Siekierka JJ, Hung SH, Poe M, et al. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 1989; 341: 755-757.
26. Miyata Y, Chambraud B, Radanyi C, et al. Phosphorylation of the immunosuppressant FK506-binding protein FKBP52 by casein kinase II: Regulation of HSP90-binding activity of FKBP52. Proc Natl Acad Sci USA 1997; 94: 14500-14505.
27. Zhang X, Clark AF, Yorio T. FK506-binding protein 51 regulates nuclear transport of the glucocorticoid receptor beta and glucocorticoid responsiveness. Invest Ophthalmol Vis Sci 2008; 49: 1037-1047.
28. Van Hoof D, Passier R, Ward-Van Oostwaard D, et al. A quest for human and mouse embryonic stem cell-specific proteins. Mol Cell Proteomics 2006; 5: 1261-1273.
29. Jones MB, Krutzsch H, Shu H, et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2002; 2: 76-84.
30. Perlman EJ, Valentine MB, Griffin CA, et al. Deletion of 1p36 in childhood endodermal sinus tumors by two-color fluorescence in situ hybridization: A pediatric oncology group study. Genes Chromosomes Cancer 1996; 16: 15-20.
31. Hu J, Schuster AE, Fritsch MK, et al. Deletion mapping of 6q 21-26 and frequency of 1p36 deletion in childhood endodermal sinus tumors by microsatellite analysis. Oncogene 2001; 20: 8042-8044.
32. Palmer RD, Foster NA, Vowler SL, et al. Malignant germ cell tumours of childhood: New associations of genomic imbalance. Br J Cancer 2007; 96: 667-676.
33. Palmer RD, Barbosa-Morais NL, Gooding EL, et al. Pediatric malignant germ cell tumors show characteristic transcriptome profiles. Cancer Res 2008; 68: 4239-4247.
34. Schmidt S, Rainer J, Ploner C, et al. Glucocorticoid-induced apoptosis and glucocorticoid resistance: Molecular mechanisms and clinical relevance. Cell Death Differ 2004; 11: S45-S55.
35. Bachmann PS, Gorman R, Papa RA, et al. Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia. Cancer Res 2007; 67: 4482-4490.
36. Gu L, Gao J, Li Q, et al. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis. Leukemia 2008; 22: 2091-2096.
37. Kaspers GJ, Pieters R, Klumper E, et al. Glucocorticoid resistance in childhood leukemia. Leuk Lymphoma 1994; 13: 187-201.
38. Ploner C, Schmidt S, Presul E, et al. Glucocorticoid-induced apoptosis and glucocorticoid resistance in acute lymphoblastic leukemia. J Steroid Biochem Mol Biol 2005; 93: 153-160.
39. Pottier N, Yang W, Assem M, et al. The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia. J Natl Cancer Inst 2008; 100: 1792-1803.
40. Renner K, Ausserlechner MJ, Kofler R. A conceptual view on glucocorticoid-induced apoptosis, cell cycle arrest and glucocorticoid resistance in lymphoblastic leukemia. Curr Mol Med 2003; 3: 707-717.
41. Schmidt S, Irving JA, Minto L, et al. Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor. FASEB J 2006; 20: 2600-2602.
42. Tissing WJ, Lauten M, Meijerink JP, et al. Expression of the glucocorticoid receptor and its isoforms in relation to glucocorticoid resistance in childhood acute lymphocytic leukemia. Haematologica 2005; 90: 1279-1281.
43. Schmidt S, Rainer J, Riml S, et al. Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia. Blood 2006; 107: 2061-2069.
44. Wochnik GM, Ruegg J, Abel GA, et al. FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J Biol Chem 2005; 280: 4609-4616.
45. Zhao G, Shi L, Qiu D, et al. NF45/ILF2 tissue expression, promoter analysis, and interleukin-2 transactivating function. Exp Cell Res 2005; 305: 312-323.
46. Rodriguez A, Roy J, Martinez-Martinez S, et al. A conserved docking surface on calcineurin mediates interaction with substrates and immunosuppressants. Mol Cell 2009; 33: 616-626.
47. Chambraud B, Radanyi C, Camonis JH, et al. FAP48, a new protein that forms specific complexes with both immunophilins FKBP59 and FKBP12. Prevention by the immunosuppressant drugs FK506 and rapamycin. J Biol Chem 1996; 271: 32923-32929.
48. Krummrei U, Baulieu EE, Chambraud B. The FKBP-associated protein FAP48 is an antiproliferative molecule and a player in T cell activation that increases IL2 synthesis. Proc Natl Acad Sci USA 2003; 100: 2444-2449.
49. Tissing WJ, Meijerink JP, den Boer ML, et al. mRNA expression levels of (co)chaperone molecules of the glucocorticoid receptor are not involved in glucocorticoid resistance in pediatric ALL. Leukemia 2005; 19: 727-733.
50. Meijsing SH, Pufall MA, So AY, et al. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 2009; 324: 407-410.